Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors

Purpose: Combinations of immune-checkpoint inhibitors (ICI) with other cancer therapies have been approved for advanced cancers in multiple indications, and numerous trials are under way to test new combinations. However, the mechanisms that account for the superiority of approved ICI combinations relative to their constituent monotherapies remain unknown. Experimental Design: We analyzed 13…

Read the full article here

Source: Clinical Cancer Research

Categories: Latest Headlines, Oncologists1

Tags: GI22

Tweets with this article

Yousuf Zafar, MD MHS

With all the talk of IO and combo tx in GI cancer, let’s not forget: the more we learn about cancer therapy, the less we know. Interesting study showed that combo ICI might not be synergistic at all. The lesson? Tolerability is key! #GI22 https://t.co/d1f4GJrOc9

Get a Ph.D. in health policy — from a single Powerpoint slide

Looking for an actually concise explanation of a half-century’s worth of research and arguments about health care spending in the U.S.? You’re in luck.

Yousuf Zafar, MD MHS October 4, 2022

#MyFirstASCO: Memories from 57 years of annual meetings – The Cancer Letter

The ASCO annual meeting began in 1964 as a group of 51 physicians finalizing the bylaws of the organization—and has since turned into a much-anticipated…

Yousuf Zafar, MD MHS June 3, 2022

Cancer-Related Spending and Mortality Rates in High-Income Countries

This cross-sectional study assesses whether cancer mortality rates in 2020 were lower in countries with higher cancer-related spending and estimates across countries the incremental cost…

Yousuf Zafar, MD MHS June 3, 2022

Kaiser Permanente doubles affordable housing investment to $400M

Kaiser Permanente has doubled its social impact investment fund to $400 million, unlocking more money to build affordable housing and other value-based investments. | Kaiser…

Yousuf Zafar, MD MHS April 18, 2022

Using Circulating Tumor DNA for Colon Cancer Adjuvant Therapy: To Be or Not to Be?

Detection of circulating tumor DNA (ctDNA) postoperatively is prognostic for recurrence for patients with stage III colon cancer. Those with sustained undetectable ctDNA will likely…

Seth Corey, MD MPH February 14, 2022

AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care

The coronavirus disease 2019 (COVID-19), now entering its third year, has led to major disruptions to economic stability, health care, and scientific research across the…

Cancer Research February 14, 2022

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors

Purpose: Entrectinib potently inhibits TRKA/B/C and ROS1, and previously induced deep (objective response rate [ORR] 57.4%) and durable (median duration of response [DoR] 10.4 months)…

Jarushka Naidoo February 13, 2022

Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis

Purpose: Cerebrospinal fluid (CSF) cytology is the gold standard diagnostic test for breast cancer leptomeningeal metastasis (BCLM), but has impaired sensitivity, often necessitating repeated lumbar…

Jarushka Naidoo February 13, 2022

Tumor Genomic Testing for >4000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

Purpose: Successful implementation of genomic testing in clinical practice is critical for identification of men with metastatic castration-resistant prostate cancer (mCRPC) eligible for olaparib and…

NatureReviewsUrology February 11, 2022

A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors

Purpose: Glutamine is a critical fuel for solid tumors. Interference with glutamine metabolism is deleterious to neoplasia in preclinical models. A phase I study of…

Steven Artandi, MD, PhD February 11, 2022

Related Articles